FibroGen, Inc.
FGEN
$8.12
$0.040.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 774.80% | 35.07% | -89.20% | 104.25% | -99.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 774.80% | 35.07% | -89.20% | 104.25% | -99.69% |
| Cost of Revenue | -94.22% | -81.69% | -83.70% | -97.97% | -69.59% |
| Gross Profit | 99.62% | 85.39% | 79.40% | 101.70% | 21.84% |
| SG&A Expenses | -43.44% | -52.66% | -51.50% | 283.57% | -63.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -77.97% | -72.56% | -76.48% | -79.60% | -67.85% |
| Operating Income | 81.57% | 74.88% | 69.92% | 94.79% | 42.73% |
| Income Before Tax | 72.78% | 70.92% | 65.81% | 90.89% | 23.99% |
| Income Tax Expenses | -- | 67.26% | -71.43% | 101.14% | -96.43% |
| Earnings from Continuing Operations | 72.78% | 70.95% | 65.82% | 90.88% | 24.09% |
| Earnings from Discontinued Operations | 585.02% | -80.73% | 32.84% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,274.41% | 51.09% | 114.09% | 131.98% | 73.14% |
| EBIT | 81.57% | 74.88% | 69.92% | 94.79% | 42.73% |
| EBITDA | 81.77% | 74.93% | 70.09% | 95.01% | 41.44% |
| EPS Basic | 1,267.73% | 51.68% | 113.81% | 131.39% | 73.75% |
| Normalized Basic EPS | 78.19% | 72.10% | 66.73% | 93.70% | 42.94% |
| EPS Diluted | 1,267.73% | 51.68% | 113.81% | 131.39% | 73.75% |
| Normalized Diluted EPS | 78.19% | 72.10% | 66.73% | 93.70% | 42.94% |
| Average Basic Shares Outstanding | 0.57% | 1.23% | 1.99% | 3.63% | 2.32% |
| Average Diluted Shares Outstanding | 0.57% | 1.23% | 1.99% | 3.63% | 2.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |